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Abstract 
Lignans are biologically active phenolic compounds related to lignin, produced in different 
plants. Arctigenin, a dibenzylbutyrolactone-type lignan, has been used as a neuroprotective 
agent for the treatment of encephalitis. Previous studies of cultured rat cerebral cortical 
neurones raised the possibility that arctigenin inhibits kainate-induced excitotoxicity. The 
aims of the present study were: 1) to analyse the effect of arctigenin on normal synaptic 
activity in ex vivo brain slices, 2) to determine its receptor binding properties and test the 
effect of arctigenin on AMPA/kainate receptor activation and 3) to establish its effects on 
neuronal activity in vivo. Arctigenin inhibited glutamatergic transmission and reduced the 
evoked field responses. The inhibitory effect of arctigenin on the evoked field responses 
proved to be substantially dose dependent. Our results indicate that arctigenin exerts its 
effects under physiological conditions and not only on hyper-excited neurons. Furthermore, 
arctigenin can cross the blood-brain barrier and in the brain it interacts with kainate sensitive 
ionotropic glutamate receptors. These results indicate that arctigenin is a potentially useful 
new pharmacological tool for the inhibition of glutamate-evoked responses in the central 
nervous system in vivo.  
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1. Introduction 
Lignans are important biologically active phenolic compounds related to lignin, produced 
in different plants, for example in tribe Cynareae, such as Arctium, (Boldizsár et al., 2010a), 
Cirsium (Boldizsár et al., 2010b) species, Forsythia (Maiada et al, 1990) or Torreya (Zhao et 
al., 1999) plants. These compounds are present either in free aglycone or in glycosylated form 
in a wide variety of plants in wooden parts, roots, leaves, flowers, fruits or seeds. Due to their 
antibacterial, antiviral, antifungal, antioxidant and insecticidal properties they are likely to 
play an important role in the plants’ defence against a variety of pathogenic agents (Harmatha 
and Dinan 2003; Wink, 2006).  
Among lignans, the dibenzylbutyrolactone-type arctigenin (ATG) has special 
importance. In addition to the neuroprotective activity of arctigenin, it also shows significant 
anti-tumor (Mervai et al., 2015), antiviral (Hayashi et al., 2010; Zhang et al., 2014), anti-
inflammatory (Cho et al., 2004; Zhao et al., 2009; Hyam et al., 2013,) and phytoestrogenic 
(Turner et al., 2007; Landete, 2012) activities, highlighting the importance of this natural 
lignan aglycone.  
As a neuroprotective agent (Jang et al., 20012; Ma et al., 2010), arctigenin has been used 
as a neuroprotective medicine in traditional medication for treatment of encephalitis (Saxena 
and Dhole, 2008; Zhang et al., 2014). Additionally, previous studies of cultured rat cerebral 
cortical neurones suggested that arctigenin inhibits the excitotoxic effect of kainate by binding 
to non-NMDA type glutamate receptors (Jang et al., 2002). However, the direct effects of 
arctigenin on normal neuronal activity have not been established. Arctigenin is a lipophilic 
molecule that likely to penetrate the blood-brain-barrier, but this has not been demonstrated 
experimentally. Therefore, the aims of the present study were: 1) to analyse the effect of 
arctigenin on synaptic activity in ex vivo brain slice experiments, 2) to determine its receptor 
binding properties and effects on AMPA/kainate receptor activation and 3) to establish its 
penetration through the blood-brain barrier and effects on neuronal activity in vivo. 
 
2. Materials and methods 
Male Wistar rats (150-280 g for ex vivo and 360-525 g for in vivo studies, Toxicoop, 
Hungary) were used for all experiments in accordance with the European Communities 
Council Directive (86/609/EEC) and with the guidelines of the Eötvös Loránd University 
Animal Care and Use Committee (p.n.: XIV-I 001/515-4/2012). All possible efforts were 
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made to minimize animal suffering and to reduce the number of animals used. Rats were 
maintained in 12 h light/dark cycle and controlled temperature (22±2 ◦C). Standard pellet food 
and tap water were available ad libitum. 
Arctigenin purchased from Tocris Bioscience (Avonmouth, UK) was dissolved in 3% 
DMSO containing sterile physiological saline and stored as 1 mM stock solution at -20oC. All 
other chemicals were purchased from Sigma-Aldrich (Hungary) if not stated otherwise. 
2.1. Slice preparation and electrophysiological recording 
Electrophysiological recordings were carried out on 64 coronal slices of somatosensory 
cortex prepared from 18 adult rats as previously described (Világi et al., 2009). Rats were 
decapitated in deep chloral-hydrate (350 mg/kg) anaesthesia. Brains were quickly removed 
and 400 m thick coronal slices were cut by a vibratome. After 1 h regeneration period in the 
incubation solution, slices were transferred to a Haas-type recording chamber (Experimetria 
Ltd., Budapest, Hungary) and perfused (2.0 ml/min) with standard artificial cerebrospinal 
solution (ACSF). The solution was saturated with carbogene (5% CO2, 95% O2) at 331C. 
The composition of the ACSF solution was (in mM): 126 NaCl; 26 NaHCO3; 1.8 KCl; 1.25 
KH2PO4; 1.3 MgSO4; 2.4 CaCl2; 10 glucose.  
Glass microelectrodes filled with 1 M NaCl (8-10 M) were positioned as recording 
electrodes into the lower part of layer 3 (L3) of the somatosensory cortex, while bipolar 
tungsten stimulating electrodes were placed directly below the recording electrodes at the 
border of the white and grey matters. Duration of the stimulation square voltage pulses was 
100 µs and the amplitude was gradually varied between threshold and supramaximal values. 
Signals were amplified by an Axoclamp2A amplifier (Axon Instruments Inc., Union City, 
CA), digitalized by an A/D converter (NI-6023E, National Instruments, Austin, Texas) and 
recorded with the SPEL Advanced Intrasys computer program (Experimetria Ltd., Budapest, 
Hungary). Single-shock stimulation evoked a characteristic field response, which consists of 
an early (N1) synaptic component (mean latency: 6.1 ms), which was followed by a positive 
(P1) and a late negative (N2) peaks, while sometimes but not always a previous, non-synaptic, 
antidromic component also appeared (Fig. 1). 
The viability of each slice was tested at the beginning of the recording session. If the 
peak-to-peak amplitude of the maximal evoked response (N1-P1) was smaller than 1.0 mV, 
the slice was excluded from the experiments. Slices were continuously stimulated with 
medium-strength stimuli at a rate of 0.1 Hz. Stimulus threshold (T) was determined 15 min 
after placing the slices into the recording chamber. Subsequently, 0.1 Hz continuous 
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stimulation was applied with 2T for 30 min to record control evoked responses, and at the end 
of this period 10 evoked responses at 2T were stored.  
To test the inhibitory effect of arctigenin at three different concentrations, standard 
perfusion solution was switched to arctigenin containing solution (stock solution was diluted 
to a final concentration of 1, 10 or 20 M in the perfusion solution) for 30 min following the 
first measurement of evoked field potential (EFP) at 2T. At the end of arctigenin application 
the 10 test responses at 2T were also stored. 
Recorded data were analysed using the SPEL (Solution Pack for Experimental 
Laboratories) Advanced Intrasys computer program (Experimetria Ltd., Budapest, Hungary). 
Each experimental group contained 7-8 independent records obtained from different animals. 
The early component was characterized by the peak amplitude of the early monosynaptic N1 
component and by peak-to-peak amplitude of N1-P1 polysynaptic waves (Fig. 1A). The 
amplitude of the second negative (N2), late component was also determined. During the 
statistical analysis interleaved control and treated groups were compared. In each series of 
experiments one-way ANOVA was performed followed by Newman-Keuls post hoc test. 
Homogeneity of variances and normal distribution of data were tested before statistical 
analysis. Results are presented as mean ± S.E.M and changes were considered to be 
significant if p < 0.05. 
2.2. Receptor ligand binding assay  
Human embryonic kidney (HEK) 293 cells transfected with the GluK1 kainate receptor 
subunit were maintained and harvested as described previously (Atlason et al., 2010). 
Membrane fractions were washed three times in binding buffer (50 mM Tris buffered with 
citric acid pH=7.4) by resuspension and centrifugation (40,000g, 20 min, 4oC). Membrane 
proteins (100 μg) were incubated for 1 h on ice with 50 nM [3H]kainate (37 MBq/ml; 
PerkinElmer Life and Analytical Sciences, Waltham, MA) in the absence and in the presence 
of 0.01-1 mM arctigenin. Non-specific radioligand binding was measured in the presence of 
unlabelled kainate (1 mM; Tocris Bioscience, Avonmouth, UK). Receptor-ligand complexes 
were recovered using a filter in a Brandel cell harvester (model M-30; Brandel, Gaithesburg, 
MD, USA) and washed three times using 4 ml of binding buffer. Radioligand binding was 
measured using a scintillation counter (LS6500; Beckman, High Wycombe, UK).  
2.3. Cobalt-uptake assay 
Slices were obtained from six animals to test changes in Co2+ uptake as a consequence of 
arctigenin treatment. Slice preparation was carried out in the same way as described under 
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2.1. The thickness of the slices was, however, 250 m. From each rat 8-10 slices were stained 
and evaluated. The procedure was performed as described previously (Pruss et al., 1991). 
Briefly, slices were incubated in a Ca2+ free incubation solution for 5 min at room temperature 
(~20oC) before placement into an uptake buffer (in mM) (13 sucrose, 57.5 NaCl, 5 KCl, 2 
MgCl2, 1 CaCl2, 12 glucose, 10 HEPES) supplemented with 5 mM CoCl2 and 100 μM 
kainate. Slices incubated in the same solution without kainate served as background controls. 
Half of the brain slices were also exposed to either 10 or 20 μM arctigenin in uptake buffer. 
Incubation lasted for 20 min at 22oC, and then slices were rinsed once in the uptake buffer and 
incubated in the same buffer containing 2 mM EDTA to remove non-specifically bound Co2+. 
Following that, slices were rinsed twice with the uptake buffer, and Co2+ was precipitated by 
incubation in a 0.12% (NH4)2S solution for 5 min. During this procedure, dark CoS precipitate 
was formed in the cells. At the end, slices were fixed in 4% paraformaldehyde for 30 min and 
mounted in glycerin for image analysis. 
Co2+-stained slices were placed on an Olympus CH-2 microscope equipped with an 
Olympus Camedia C4040-Zoom digital camera connected to a PC running AnalySIS 3.2 
Docu (Soft Imaging System) software. Images were captured by the CCD camera under the 
control of AnalySIS 3.2 Docu software. Exposure time was fixed during image acquisition. 
Images were taken at 4-fold magnification and converted to 8-bit grey scale images. 
Subsequent densitometry analysis was made by custom written Mathworks Matlab software 
as follows: perpendicular to the pial surface a rectangular shaped region of interests (ROI) 
was defined in the dimensions of 450x1800 μm spanning all layers of the neocortex. Optical 
density (OD) was measured in arbitrary units using 256 grey levels of images within ROIs, 
followed by an averaging of OD values in each row of pixels in the ROI. OD of a 20x20 pixel 
area out of the slice was determined in each slide as background and data were always 
corrected with this OD value. The distance between the pial surface and the corpus callosum 
was divided into 20 equal divisions for the comparison of corresponding regions in various 
treatment groups. These divisions were correlated to cortical layers on the basis of previous 
studies (Skoglund et al., 1996). Original continuous OD distribution was interpolated to the 
20 divisions and correlated to cortical layers. In all experiments the corrected OD values of 
kainate-stimulated (control) slices were expressed as a percentage of corrected OD values of 
slices without kainate application. The same calculation was performed for arctigenin treated 
brain slices. 
2.4. Test of the crossing of blood-brain barrier 
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Rats (n=4) received 20 mg/kg arctigenin intraperitoneally (i.p.). Physiological saline 
solution containing arctigenin was injected at body temperature in a volume of 4 ml. After 20 
min, rats were sacrificed and perfused transcardially with 150 ml ice cold ACSF to wash out 
the blood from the brain. Brain were removed, rinsed, weighed and immediately snap-frozen 
in liquid nitrogen for lyophilisation. Samples were extracted in 2.0 mL methyl alcohol and 
dialysed to obtain a protein free arctigenin containing extract. Microdialysis probes were 
hollow fibres (Travenol, cut-off at 5000 Da, o.d. 0.2 mm, length of the active surface: 3 mm) 
adjusted into 23-Gauge, stainless steel tubing. Methyl alcohol was used for perfusion (2.0 
µL/min for 10 min). The 20 μL of arctigenin containing dialysate was analysed by high-
performance liquid chromatography (HPLC) using UV detection. The HPLC system consisted 
of two Pharmacia LKB pumps and a VWM 2141UV detector (Pharmacia LKB Biochrom, 
Cambridge, UK). Column: GraceSmart RP18 (5_m), 150 x 4.6mm (Grace Davison Discovery 
Sciences Lokeren, Belgium). Gradient elution was carried out at 20-22oC. Eluents: eluent A, 
acetonitrile/0.07M acetic acid 15/85 (v/v), eluent B, acetonitrile/0.07M acetic acid 85/15 
(v/v). Gradient: 15% B → 30% B over 5 min, 30% B → 44% B over 7 min, 44% B → 100% 
B over 5 min. UV detection was carried out at λ = 280 nm. Retention time of arctigenin was 
11.48 min. 
2.5. In vivo recording 
Rats (n=6) were anesthetized with urethane (1.2 g/kg, i.p.) and fixed in a stereotaxic 
frame (David Kopf) with the top of the skull set horizontal to comply with the rat brain atlas 
of Paxinos and Watson (Paxinos and Watson, 1998). A 4 x 3 mm craniotomy centred 1.5 mm 
posterior to Bregma and 1.5 mm lateral to the midline was made to expose the hind limb 
representation area in the right hemisphere. The dura mater was left intact during the whole 
experiment. Rectal temperature was maintained at 37 °C Arctigenin solutions were also 
applied i.p. Arctigenin and respective saline solutions were injected at body temperature in a 
volume of 2 ml in case of the 20 mg/kg dose (n=4) while injection volume was 4 ml in case of 
the 50 mg/kg dose (n=2). To test possible non-specific effect of the injections, recording 
sessions started with the application of control saline solutions followed by 1-hour long 
recording. Then arctigenin was applied and its effect was recorded for 1 h. 
Hind limb (HL) area of the primary somatosensory cortex (SI) was localized as described 
previously (Toth et al., 2008). A 1.1 mm stainless steel reference electrode (Fine Science 
Tools, USA) was placed above the cerebellum. A 16-channel vertical electrode array was 
positioned 1-1.2 mm below the dura (Neuronelektród Ltd., Budapest, Hungary) to record 
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evoked extracellular field potentials (EFPs) from different cortical layers at the same 
recording site. After insertion of the recording array, two stimulating needle electrodes were 
inserted into the HL close to the ankle to enable electrical stimulation of the tibial nerve. 
Stimuli for EFPs recording were square-wave pulses generated by a stimulator (Master8, 
A.M.P.I., Jerusalem, Israel), and delivered through a Master8 ISO-Flex stimulus isolation 
unit. The threshold stimulus voltage was defined as the lowest intensity that elicited minimal 
movement in the hind paw (4.25 V ± 0.28 V). During the whole experiment, stimulus strength 
twice the threshold was used (2T) with 200 μs duration. Stimulus rate was set to 0.1 Hz and a 
total of 360 EFPs were recorded in 1 h. EFPs were recorded in 2000 ms long blocks (1000 ms 
pre-stimulus, 1000 ms post-stimulus periods). 
EFP signals were fed to a 16-channel differential amplifier (Supertech Ltd., Pecs, 
Hungary), conditioned (filter: 0.1 Hz–1000 Hz, gain: 5000x) then digitalized at 3 kHz with 16 
bit resolution (Labview; National Instruments, Austin, TX, USA). All data were stored on 
hard disk for off-line analysis.  
Parameters of the EFPs recorded were calculated from layer 3 and layer 5. Single EFPs 
were averaged in 10 min long blocks where every block contained 60 responses. Amplitude 
and latency values of the characteristic waves were determined in these blocks and expressed 
as mean and standard error of the means (S.E.M). The areas under the curves (AUC) were 
also calculated to take into account the potential changes in the width of the different waves 
of the EFPs. For this, the baseline of the curves was shifted to zero. Numerical integrate 
values were calculated in Microsoft Excel using the trapezoidal rule (Burden and Faires, 
2004). As duration of the P1 wave in EFPs recorded from layer 3 showed large variations, 
numerical integrate was calculated between predefined time points of the P1 wave (4 ms and 
45 ms). Layer 5 EFPs were highly uniform in shape and in this case integrate was calculated 
the start and end points of the N1.  
Amplitude, latency and AUC differences seen in control vs. arctigenin responses were 
compared statistically by one-way ANOVA followed by Student-Newman-Keuls post hoc 
test. Assumption that data are sampled from populations that follow Gaussian distributions 
was checked by the test of Kolmogorov and Smirnov. Statistical tests were performed using 
Instat (GraphPad, San Diego, CA, USA). Statistical significance was accepted at the p < 0.05 
level. At the end of the experiment, position of the recording array was marked using direct 
current injections, and confirmed by histological analysis. 
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3. Results 
3.1. Evoked responses in slice experiments  
In control slices, the mean of the peak amplitude of N1 component (Fig. 1A) was -
2.03±0.20 mV (n=8) at the end of the 30 min recording (Fig. 2A). While the application of 1 
μM arctigenin produced no significant change (-1.57±0.13 mV, p=0.081), the 10 μM and 20 
μM arctigenin significantly reduced the amplitude of the N1 component of EFP (-1.27±0.09 
mV, p=0.005**; n=7; and -0.86±0.09 mV, p=0.0003***; n=7) at the end of the 30 min 
incubation period. The peak-to-peak amplitude of the polysynaptic N1-P1 component of the 
evoked field potential was 2.31±17.7 mV (n=8) at the end of the recording (Fig. 2B). While 
the application of 1-10 μM arctigenin produced no significant change (1 μM: 1.92±0.18 mV, 
p=0.243; 10 μM: 1.92±0.18 mV, p=0.066; n=7), 20 μM arctigenin considerably reduced the 
EFP amplitude of N1-P1 (0.92±0.08 mV, p=0.0024**; n=7) at the end of the 30 min 
incubation period. 
The effect of arctigenin on N2 component of EFP was also tested. In control slices after 
30 min -0.65±0.13 mV (n=8) evoked field potential amplitude was measured. Arctigenin 
applied in 1, 10 and 20 μM concentrations had no significant effect on evoked field potential 
amplitude (-0.41±0.15 mV, (p=0.805, n=7), -0.20±0.04 mV, (p=0.486, n=7) and  
-0.12±0.02 mV (p=0.039; n=7), respectively).  
3.2. Receptor binding analysis 
Cell membrane fraction from transfected HEK 293 cells was used to analyse the effect of 
arctigenin on [3H]kainate binding to GluK1 kainate receptor subunit (Fig. 3) (Atlason et al., 
2010). [3H]kainate binding assays performed in the presence of different arctigenin 
concentrations (0.01-1 mM) revealed a significant reduction in [3H]kainate binding activity to 
GluK1 at 1 mM (Fig. 3; n=4, p<0.01; Student’s t-test).  
3.3. Alterations in Co2+ -uptake 
Following kainate activation, Co2+ crosses the plasma membrane through Ca2+ permeable 
AMPA and kainate receptors (Mayer and Westbrook, 1987). The distribution and relative 
intensity of the signal produced by CoS precipitation with and without kainate treatment (Fig. 
4A) can be compared using densitometry (Fig. 4B). Arctigenin effectively and dose-
dependently reduced the AMPA/kainate receptor activation and subsequent Co2+ uptake 
especially in the supragranular layers of somatosensory cortex (Fig. 4B). Overall, OD 
associated with kainate-induced Co2+ uptake was significantly reduced in most layers of the 
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somatosensory cortex in arctigenin-treated slices (Fig. 4). The most prominent changes of OD 
was identified in layers 2/3 in the control kainate-treated slices (193.2±23.6%, n=6), where 10 
or 20 μM arctigenin application parallel with kainate treatment reduced the changes of OD to 
122.3±21.5% and 85.1±31.6%, respectively. The level of decrease was significant in these 
layers in cases both of 10 and 20 μM arctigenin treatment (n=6-6, p<0.02*). 
3.4. Arctigenin level in the brain following intraperitoneal application 
These measurements were carried out to establish the penetration of arctigenin into the 
brain tissue through the blood-brain barrier. Substantial amount of arctigenin was detectable 
in the brain tissue 20 min after 20 mg/kg intraperitoneal application of the lignan, which 
indicates that it can cross the blood-brain barrier. The average wet brain weight was 
1.47±0.11 g (n=4). The arctigenin content was 3.19±0.5x10-7g/1 g wet brain tissue. 
3.5. Evoked field potentials in vivo 
Tibial nerve stimuli elicited clear EFPs in the cortex both in the control and arctigenin-
treated animals. Short latency responses (up to 50 ms) in layer3 EFPs showed a characteristic 
positive peak (P1), which was highly variable in duration (Fig. 5A, top). EFPs showed slight 
potentiation in response to the consecutive stimulation during the control recordings. By the 
end of the one-hour-long recording in layer 3, P1 amplitude increased to 84.66±11.3 µV from 
the initial 67.22±8.63 µV value seen in the first 10 min long block. Similar increase was seen 
in the N1 amplitude of layer5 responses, but it was smaller (7.5±43.1 % change; data not 
shown). After the injection of arctigenin, P1 amplitude significantly decreased in layer 3 (Fig. 
2) compared to the value of the last 10 min block of the control recording taken as baseline. 
The strongest decrease was seen in the first 10 min period following arctigenin application, 
the mean amplitude was only 59.18 ±12.96 µV which meant 30 % decrease (p=0.623, n=6). 
The decrease persisted for longer time, the amplitude was 75.6 ±18.17 µV (p=0.623, n=6) 30-
min post-injection. In layer5, EFP amplitude did not change significantly after arctigenin 
injections (data not shown). 
There was a tendency to decrease in the AUC values in case of layer3 EFPs after 
arctigenin injections in the first 20 min but these changes were not statistically significant 
(Fig. 5B). 
 
 
4. Discussion 
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A previous study suggested a direct interaction between arctigenin and kainate receptors 
in cultured cerebrocortical neurons (Jang et al., 2002). This study demonstrated the 
neuroprotective effect of arctigenin in an in vitro cell culture system using kainate evoked 
neurodegeneration. As a reduced [3H]kainate binding to neuronal membrane fractions was 
reported in the presence of arctigenin, the investigators proposed a selective kainate receptor 
effect. However, it was stated, that arctigenin produced similar effect as the non-NMDA 
receptor antagonist CNQX (Jang et al., 2002). This finding raised the intriguing possibility 
that arctigenin may inhibit the electrical activity of neuronal networks in vivo in the 
neocortex.  
4.1. Arctigenin significantly decreases the excitability of brain slices 
In our somatosensory cortex slice experiments the recording electrode was positioned in 
the layer 3, as the amplitude of EFPs evoked by electrical stimulation of the border of the 
corpus callosum and the grey matter is the largest in this layer (Abbes et al., 1991). Both 
AMPA, NMDA and kainate types of glutamate receptors play a role in the development of 
these evoked responses (Conti and Weinberg, 1999; Huettner, 2003). AMPA/kainate 
receptors contribute mainly to the development of early component of synaptic responses 
(Bailey et al., 2001; Campbell et al., 2007). Different types of kainate receptor subunits are 
widespread in the brain, which are expressed on neurons both pre- and postsynaptically (Ali et 
al., 2001; West et al., 2007) in hetero-tetrameric subunit assemblies (Chittajallu, 1999). While 
AMPA receptor density is rather high in the supragranular layers of the somatosensory cortex 
(Martin et al., 1993; Van Damme et al., 2003), the presence of kainate receptors is also 
demonstrated both on pyramidal cell dendrites and on interneurons, although, on pyramidal 
cell of layer 5 and layer 6 its concentration is higher (Bahn et al., 1994; Jabłońska et al., 1998; 
Bailey, et al., 2001; Zilles et al., 2002). In hippocampal slice preparations it was demonstrated 
that inhibition of presynaptic kainate receptors on pyramidal cells decrease the glutamate 
release, which reduce the activation of the postsynaptic cells (Lerma, 2006). Inhibition of 
postsynaptic kainate receptors also diminishes the membrane depolarization (Lerma, 2006). 
Our experiments demonstrate that arctigenin directly binds to GluK1 kainate receptor 
subunits. Also, 10 μM arctigenin effectively reduces the amplitude of the early monosynaptic 
components of EFPs. The inhibitory effect of arctigenin on the evoked field responses proved 
to be substantially dose dependent, however, the late component was reduced only by the 
largest dose of arctigenin. Mainly AMPA/kainate receptor activation underlies the first 
synaptic components of evoked field potentials, so the inhibitory effect of arctigenin on 
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synaptic efficacy indicates that it may exerts effect not only at pathophysiological but also at 
normal physiological condition on AMPA/kainate receptor. The smaller effect of arctigenin 
on late component is consistent with previous studies, because primarily the NMDA receptor 
activation is responsible for the development of the late component of EFP, and arctigenin 
does not seem to affect these receptors (Conti and Weinberg, 1999).  
4.2. Arctigenin inhibits AMPA/kainate type ligand-gated ion channel activation 
Co2+ can cross neuronal plasmamembrane through activated AMPA/kainate receptors 
instead of Ca2+, accordingly the alteration of Co2+ staining refer to modified non-NMDA type 
ligand gated ion channel activation (Williams et al., 1992). We detected, that kainate-induced 
Co2+ uptake was not uniform along the column perpendicular to the pial surface in the 
somatosensory area of control slices, in the layer 2/3 is higher than in layer 5 or layer 6. Co2+ 
uptake was effectively reduced in the presence of arctigenin, which was particularly 
noticeable in the supragranular layers. As kainate can bind not only to kainate receptors, but 
also to AMPA receptors, we have to take into consideration that AMPA receptors might also 
be affected by arctigenin (Iino et al, 1990). 
4.3. Arctigenin reduces synaptic activity in vivo through its antagonistic effects on 
glutamate receptors 
We have demonstrated that arctigenin can cross the blood-brain barrier and appears in the 
brain following intraperitoneal administration. The in vivo electrophysiological experiments 
revealed that arctigenin has an antagonistic effect on glutamate-evoked responses, which also 
indicate that arctigenin can get into the cortex. The inhibitory effect proved to be more 
prominent in the outer layers of the cortex, which may be due to the differential distribution of 
different ionotropic glutamate receptors. Our results indicate that glutamatergic transmission 
can be modulated in vivo by arctigenin, which is a new type of glutamate receptor antagonist, 
and could be a lead compound for the development of neuroprotective drugs. On the basis of 
our experiments we can conclude that arctigenin may exerts its effect on neurons in 
physiological conditions not only on neurons overexcited i.e. by kainic acid application. 
Arctigenin and its derivatives, may lead to improved treatment strategies in different neural 
diseases like schizophrenia, autism, bipolar disorders, mental retardation together with 
epileptiform diseases, chronic pain or migraine (Contractor et al., 2011). However, the 
potentially broader effects of arctigenin on other ionotropic and metabotropic glutamate 
receptors also need to be considered and investigated in future studies. 
5. Conclusions 
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Several biologically active compounds possess neuroprotective effects. It was proved that 
arctigenin, a lignan produced by different plants, effectively protects cultured neurons from 
excitotoxicity via the inhibition of kainate sensitive ionotropic glutamate receptors. Here we 
demonstrated that arctigenin can cross the blood-brain barrier, reduces the activity of 
ionotropic glutamate receptors, and inhibits normal electrical responses both in brain slices 
and in living animals. 
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Figure legends:  
 
Fig. 1. Original records of evoked field potentials (EFPs) in ex vivo cortical slice evoked 
by electrical simulation of the border of the white and grey matter (A) and in vivo by electrical 
stimulation of tibial nerve (B). Panel A: The first, early synaptic component was 
characterized by the monosynaptic N1 component amplitude and by the polysynaptic N1-P1 
peak-to-peak amplitude. Panel B: The response evoked in cortical layer 3 was characterised 
by the positive wave (P1) amplitude. 
 
Fig. 2. Arctigenin (ATG) reduced the amplitude both the monosynaptic and polysynaptic 
part of the early component of the evoked field potentials. The effect of arctigenin on 
extracellularly recorded evoked potentials was tested in ex vivo slice preparations. Insert 
shows original record of a control evoked response (black line) and the effect of application of 
20 μM arctigenin on it (gray line). Panel A: dose dependent suppression of the early 
monosynaptic component (N1) of field potentials by ATG at 2T stimulus intensity. ATG was 
able to reduce significantly the amplitude of N1 component of the evoked response applying 
in 10 μM and 20 μM concentration (data are presented in absolute value). Panel B: 
suppression of the early, polysynaptic component (N1-P1) of field potentials by ATG was 
also dose dependent at 2T stimulus intensity. ATG was able to reduce the (N1-P1) component 
in 20 μM concentration (n=8 in each groups).  
**p< 0.005, ***p< 0.0003. Statistical significance was checked by one-way ANOVA, 
followed by Newman-Keuls post hoc test.  
 
Fig. 3. Arctigenin (ATG) inhibits [3H]kainate binding to GluK1 kainate receptor subunit 
at 1 mM.  Membranes from HEK 293 cells stably transfected with GluK1 were incubated 
with 50 nM [3H]kainate and varying concentrations of arctigenin, with unlabelled kainate 
(KA) as positive control. Unlabelled kainate and 1 mM arctigenin significantly inhibited 
[3H]kainate binding to GluK1. n=3, *p<0.05, **p<0.01; Student’s t-test. 
 
Fig. 4. Arctigenin (ATG) suppresses Co2+ uptake in supragranular layers of 
somatosensory cortex. Panel A shows representative images of Co2+ uptake patterns in 
treatment groups: first and second columns represent sections without and with kainate 
(KAIN) application, respectively. Images ATG 10 μM and ATG 20 μM represent arctigenin-
18 
 
treated sections with together with kainate application. The optical density changes (ΔOD) are 
shown on Panel B. Both concentration of arctigenin reduced the Co2+ permeability of cells in 
supragranular layers, especially in layer 3. L1-6 represent cortical layers. n=6 in each groups, 
*p<0.05; Student’s t-test.  
 
Fig. 5. Characteristics of EFP waves evoked by electrical stimulation of the HL (panel A) and 
illustration of the AUC calculated in this work (panel B). Insert illustrates the evoked 
response showed a characteristic positive wave (P1) in layer 3. Amplitude of P1 was 
calculated as a deviation from the pre-stimulus baseline. Black curve shows averaged EFP 
from the baseline period while grey curve represents averaged EFP after 10 min arctigenin 
application. Stimulus onsets are marked by arrow. Note that stimulus artefacts were removed 
from the averaged EFP curves. Panel A: changes of P1 wave amplitude after arctigenin 
application compared to baseline in layer 3 (n=6). Averaged values of the last control block 
(between 50 and 60 min from the time point of the control injection) were taken as baseline 
(100 %). Each block plotted represents the average of 60 individual EFPs per rat. Statistical 
significance was checked by one-way ANOVA followed by Student-Newman-Keuls post hoc 
test. Significance level: * - p < 0.05. Data are expressed as mean and S.E.M. Panel B: AUC 
changes of the EFP in layer 3. For the calculation of AUC values, the baseline of the curves 
was shifted to zero then the numerical integrate of the ruled area was determined in case of 
layer3 EFPs. Averaged EFP curves were calculated from single EFPs recorded in the last 
control block (between 50 and 60 min from the time point of the control injection, n=60 
EFPs) then AUC of the averaged EFP was determined. Then the same procedure was applied 
for the EFPs recorded after the arctigenin injections. Statistical significance was checked by 
one-way ANOVA followed by Student-Newman-Keuls post hoc test. Data are expressed as 
mean and S.E.M. 
 
 
